All patients self-identified as non-White and nearly 69% of treated subjects had objectively measured Fitzpatrick skin types IV through VI The IL-23 inhibitor guselkumab demonstrated efficacy out to 100 weeks in the treatment of psoriasis across a spectrum of skin types, according to poster research presented at the 2026 annual meeting of the American Academy of Dermatology (AAD) in Denver. A full report will be published in the June 2026 issue of The Chronicle of Skin & Alle

Shoshana Marmon, MD, PhD Some improvements seen in skin thickness and collagen, but study designs varied Topical estrogen is emerging as a sought-after option for menopausal skin changes, but dermatologists caution that the evidence base remains limited and safety questions unresolved, according to a cover article in the Feb. 2026 issue of The Chronicle of Skin & Allergy . Patient interest in facial estrogen preparations has grown in parallel with menopause-focused marketing

Only one week is left before the 2024 Indigenous Skin Spectrum Summit and the 10th annual Skin Spectrum Summit . Register now to take...